Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regeneron Pharmaceuticals
Biotech
ESMO: Regeneron's Opdualag rival shows 57% response rate
Regeneron is back with follow-up phase 1 data for fianlimab, the company's potential rival to BMS' Opdualag, in advanced melanoma.
Gabrielle Masson
Sep 14, 2024 3:00am
FDA rejects Regeneron bispecific, delaying rival to J&J, Pfizer
Aug 21, 2024 5:48am
Pepper chemical prevents hearing loss from powerful antibiotics
Aug 8, 2024 10:40am
BioNTech, Regeneron rack up response rate win for cancer vaccine
Jul 30, 2024 6:45am
2seventy bio splits again, sending hemophilia A work to Novo
Jun 26, 2024 5:30pm
How to get cell therapies flying off-the-shelf
May 31, 2024 9:00am
